Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Microenvironmental regulation of tumor progression and metastasis

Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Understanding the tumor immune microenvironment (TIME) for effective therapy

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

The biology and management of non-small cell lung cancer

Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148 · see citing works

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · see citing works

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · see citing works

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,319 · see citing works

Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · see citing works

Nivolumab plus ipilimumab in advanced non-small-cell lung cancer

Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823 · see citing works

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798 · see citing works

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

Regulation and Function of the PD-L1 Checkpoint

Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,187 · see citing works

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · see citing works

Natural Innate and Adaptive Immunity to Cancer

Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,095 · see citing works

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027 · see citing works

Non-small-cell lung cancers: a heterogeneous set of diseases

Chen, Z., Brainson, C. F., Hammerman, P. S., Kim, C. F., & Wong, K. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3775 · Cited by 1,936 · see citing works

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · see citing works

Single-cell RNA sequencing to explore immune cell heterogeneity

Papalexi, E., & Satija, R. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.76 · Cited by 1,806 · see citing works

Cancer immunoediting and resistance to T cell-based immunotherapy

O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759 · see citing works

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662 · see citing works

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · see citing works

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · see citing works

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Mazières, J., Drilon, A. E. D. C., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,356 · see citing works

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · see citing works

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,256 · see citing works

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · see citing works

Cytokines in clinical cancer immunotherapy

Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberría, I., Aznar, M. A., Perez‐Gracia, J. L., Rodriguez-Ruiz, M. E., Ponz‐Sarvisé, M., Álvarez, E. C., & Melero, I. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,190 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Gadgeel, S. M., Rodríguez‐Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P. R., Powell, S. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03136 · Cited by 1,114 · see citing works

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 953 · see citing works

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A. A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 899 · see citing works

LAG3 (CD223) as a Cancer Immunotherapy Target

Andrews, L. P., Marciscano, A., Drake, C., & Vignali, D. A. A. (2017) · Immunological Reviews · doi:10.1111/imr.12519 · Cited by 881 · see citing works

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854 · see citing works

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839 · see citing works

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 830 · see citing works

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

Li, X., Wenes, M., Romero, P. J., Huang, S. C., Fendt, S., & Ho, P. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 745 · see citing works

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · see citing works

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Catani, J. P. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 698 · see citing works

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 661 · see citing works

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Jotte, R. M., Cappuzzo, F., Vynnychenko, I. O., Stroyakovskiy, D., Rodríguez‐Abreu, D., Hussein, M., Soo, R. A., Conter, H. J., Kozuki, T., Huang, K.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.028 · Cited by 603 · see citing works

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 581 · see citing works

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580 · see citing works

PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer

Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · see citing works

Discovery of IDO1 Inhibitors: From Bench to Bedside

Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 563 · see citing works

Improving immune–vascular crosstalk for cancer immunotherapy

Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563 · see citing works

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer

Kitajima, S., Ivanova, E., Guo, S., Yoshida, R., Campisi, M., Sundararaman, S. K., Tange, S., Mitsuishi, Y., Thai, T. C., Masuda, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0689 · Cited by 526 · see citing works

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 459 · see citing works

Inflammation-driven carcinogenesis is mediated through STING

Ahn, J., Xia, T., Konno, H., Konno, K., Ruiz, P., & Barber, G. N. (2014) · Nature Communications · doi:10.1038/ncomms6166 · Cited by 446 · see citing works

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438 · see citing works

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406 · see citing works

The promise and challenges of immune agonist antibody development in cancer

Mayes, P. A., Hance, K. W., & Hoos, A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.75 · Cited by 355 · see citing works

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342 · see citing works

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

Beavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0211 · Cited by 331 · see citing works

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321 · see citing works

Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer

Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 320 · see citing works

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40

Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 319 · see citing works

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313 · see citing works

Targeting metabolism to regulate immune responses in autoimmunity and cancer

Patel, C. H., Leone, R. D., Horton, M. R., & Powell, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0032-5 · Cited by 307 · see citing works

The therapeutic potential of targeting tryptophan catabolism in cancer

Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300 · see citing works

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer

Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 290 · see citing works

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

Kim, C. G., Kim, K. H., Pyo, K., Xin, C.-F., Hong, M. H., Ahn, B., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 282 · see citing works

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Herbst, R. S., Garon, E. B., Kim, D., Cho, B. C., Perez‐Gracia, J. L., Han, J., Arvis, C. D., Majem, M., Forster, M. D., Monnet, I., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02446 · Cited by 282 · see citing works

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

Hughes, P. E., Caenepeel, S. R., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 280 · see citing works

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

He, Y., Yu, H., Rozeboom, L. M., Rivard, C. J., Ellison, K. E., Dziadziuszko, R., Suda, K., Ren, S., Wu, C., Hou, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.019 · Cited by 269 · see citing works

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

Herbst, R. S., Arkenau, H., Santana-Dávila, R., Calvo, E., Paz-Ares, L. G., Cassier, P. A., Bendell, J. C., Penel, N., Krebs, M., Martín-Liberal, J., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30458-9 · Cited by 268 · see citing works

Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies

Wang, Q., Ju, X., Wang, J., Fan, Y. J., Ren, M., & Zhang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.028 · Cited by 265 · see citing works

STING activation in cancer immunotherapy

Su, T., Zhang, Y. L., Valerie, K. C., Wang, X., Lin, S., & Zhu, G. (2019) · Theranostics · doi:10.7150/thno.37574 · Cited by 258 · see citing works

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

Fournel, L., Wu, Z., Stadler, N., Damotte, D., Lococo, F., Boulle, G., Ségal-Bendirdjian, E., Bobbio, A., Icard, P., Trédaniel, J., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.005 · Cited by 249 · see citing works

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247 · see citing works

Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles

Rossi, A., & Maïo, M. D. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170596 · Cited by 246 · see citing works

Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer

Shukuya, T., & Carbone, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.02.015 · Cited by 245 · see citing works

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Rodríguez‐Abreu, D., Johnson, M. L., Hussein, M., Cobo, M., Patel, A. J., Sečen, N., Lee, K. H., Massutí, B., Hiret, S., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9503 · Cited by 244 · see citing works

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

Manegold, C., Dingemans, A. C., Gray, J. E., Nakagawa, K., Nicolson, M. C., Peters, S., Reck, M., Wu, Y.-L. L. C., Brustugun, O. T., Crinò, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 239 · see citing works

Humanized Mouse Xenograft Models: Narrowing the Tumor–Microenvironment Gap

Morton, J. J., Bird, G. A., Refaeli, Y., & Jimeno, A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1260 · Cited by 238 · see citing works

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1510 · Cited by 237 · see citing works

Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF‐κB and AP‐1 activation and IL‐8 and VEGF expression in human head and neck squamous cell carcinoma lines

Bancroft, C. C., Chen, Z., Yeh, J., Sunwoo, J. B., Yeh, N. T., Jackson, S., Jackson, C. R., & Waes, C. V. (2002) · International Journal of Cancer · doi:10.1002/ijc.10398 · Cited by 230 · see citing works

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Garassino, M. C., Gadgeel, S. M., Esteban, E., Felip, E., Speranza, G., Dómine, M., Hochmair, M. J., Powell, S. F., Cheng, S. Y.-S., Bischoff, H. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30801-0 · Cited by 215 · see citing works

CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment

Neo, S., Yang, Y., Record, J., Ma, R., Chen, X., Chen, Z., Tobin, N. P., Blake, E., Seitz, C., Thomas, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128895 · Cited by 205 · see citing works

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Paz-Ares, L. G., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C., Flor, M. J., Nicola, M. D., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 205 · see citing works

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

Leonetti, A., Wever, B. M. M., Mazzaschi, G., Assaraf, Y. G., Rolfo, C. D., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 201 · see citing works

Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes

Wong, D. Y. Q., Ong, W. W. F., & Ang, W. H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500934 · Cited by 186 · see citing works

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180 · see citing works

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Gettinger, S. N., Hellmann, M. D., Chow, L. Q. M., Borghaei, H., Antonia, S. J., Brahmer, J. R., Goldman, J. W., Gerber, D. E., Juergens, R. A., Shepherd, F. A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.015 · Cited by 180 · see citing works

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

Corte, C. M. D., Sen, T., Gay, C. M., Ramkumar, K., Diao, L., Cardnell, R. J., Rodriguez, B. L., Stewart, C. A., Papadimitrakopoulou, V. A., Gibson, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.009 · Cited by 180 · see citing works

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164 · see citing works

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

Shrimali, R. K., Ahmad, S., Verma, V., Zeng, P., Ananth, S., Gaur, P., Gittelman, R. M., Yusko, E. C., Sanders, C. M., Robins, H. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0292 · Cited by 161 · see citing works

Targeting the CD73-adenosine axis in immuno-oncology

Allard, D., Chrobák, P., Allard, B., Messaoudi, N., & Stagg, J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.05.001 · Cited by 161 · see citing works

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

Spigel, D. R., de Marinis, F., Giaccone, G., Reinmuth, N., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z. G., Geater, S. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz293 · Cited by 146 · see citing works

Combining chemotherapy with PD-1 blockade in NSCLC

Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 145 · see citing works

CD73–Adenosine: A Next-Generation Target in Immuno-Oncology

Allard, D., Allard, B., Gaudreau, P.-O., Chrobák, P., & Stagg, J. (2016) · Immunotherapy · doi:10.2217/imt.15.106 · Cited by 140 · see citing works

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer

Lin, J. J., Chin, E., Yeap, B. Y., Ferris, L. A., Kamesan, V., Lennes, I. T., Sequist, L. V., Heist, R. S., Mino-Kenudson, M., Gainor, J. F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.001 · Cited by 140 · see citing works

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Hong, S., Chen, N., Fang, W., Zhan, J., Liu, Q., Kang, S., He, X., Liu, L., Zhou, T., Huang, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1094598 · Cited by 136 · see citing works

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer

Gettinger, S. N., Wurtz, A., Goldberg, S. B., Rimm, D. L., Schalper, K. A., Kaech, S. M., Kavathas, P., Chiang, A. C., Lilenbaum, R., Zelterman, D. A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.008 · Cited by 135 · see citing works

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

Schaer, D. A., Geeganage, S., Amaladas, N., Lu, Z. H., Rasmussen, E. R., Sonyi, A., Chin, D., Capen, A., Li, Y., Meyer, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0433 · Cited by 132 · see citing works

The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target

Takimoto, C. H. M., Chao, M. P., Gibbs, C., Mccamish, M. A., Liu, J., Chen, J. Y., Majeti, R., & Weissman, I. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz006 · Cited by 128 · see citing works

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126 · see citing works

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures

Friedlaender, A., Drilon, A., Weiss, G. J., Banna, G. L., & Addeo, A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101978 · Cited by 118 · see citing works

Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy

Berger, G., Marloye, M., & Lawler, S. E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.007 · Cited by 116 · see citing works

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Toki, M. I., Mani, N. L., Smithy, J. W., Liu, Y., Altan, M., Wasserman, B. E., Tuktamyshov, R., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.012 · Cited by 111 · see citing works

IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors

Alshaker, H. A., & Matalka, K. Z. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-33 · Cited by 106 · see citing works

Integrated T‐cell receptor and costimulatory signals determine TGF‐β‐dependent differentiation and maintenance of Foxp3 + regulatory T cells

Gabryšová, L., Christensen, J. R., Wu, X., Kissenpfennig, A., MALISSEN, B., & O’Garra, A. (2011) · European Journal of Immunology · doi:10.1002/eji.201041073 · Cited by 94 · see citing works

Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer

Mazières, J., Kowalski, D. M., Luft, A. V., Vicente, D., Tafreshi, A., Gümüş, M., Лактионов, К. К., Hermes, B., Çiçin, İ., Rodríguez‐Cid, J. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01348 · Cited by 90 · see citing works

Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Liu, S.-Y., Dong, Z.-Y., Wu, S.-P., Xie, Z., Yan, L.-X., Li, Y.-F., Yan, H.-H., Su, J., Yang, J.-J., Zhou, Q., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.010 · Cited by 85 · see citing works

Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy

Jeong, S., & Park, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e3 · Cited by 75 · see citing works

Progress in targeting RAS with small molecule drugs

McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 63 · see citing works

Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti–PD-1 and Anti-CD137 Monoclonal Antibodies

Azpilikueta, A., Agorreta, J., Labiano, S., Perez‐Gracia, J. L., Sánchez-Paulete, A. R., Aznar, M. A., Ajona, D., Bazo, I. G., Larráyoz, M., Teijeira, Á., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.013 · Cited by 61 · see citing works

TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade In Vitro and In Vivo

Ghosh, S., Sharma, G., Travers, J., Kumar, S., Choi, J., Jun, H. T., Kehry, M. R., Ramaswamy, S., & Jenkins, D. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0836 · Cited by 61 · see citing works

Efficacy of a Cancer Vaccine against ALK -Rearranged Lung Tumors

Voena, C., Menotti, M., Mastini, C., Giacomo, F. D., Longo, D. L., Castella, B., Merlo, M. E. B., Ambrogio, C., Wang, Q., Minero, V. G., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0089 · Cited by 60 · see citing works

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

Shaw, A. T., Lee, S., Ramalingam, S. S., Bauer, T. M., Boyer, M. J., Carcereny, E., Felip, E., Han, J., Hida, T., Hughes, B. G. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9008 · Cited by 60 · see citing works

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

Kim, D., Gadgeel, S. M., Gettinger, S. N., Riely, G. J., Oxnard, G. R., Mekhail, T. M., Schmid, P., Dowlati, A., Heist, R. S., Wozniak, A. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9009 · Cited by 48 · see citing works

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

Tao, L., Huang, G., Shi, S., & Chen, L. (2013) · Medical Oncology · doi:10.1007/s12032-013-0777-3 · Cited by 45 · see citing works

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Liu, Z., Han, C., Dong, C., Shen, A., Hsu, E. J., Ren, Z., Lu, C., Liu, L., Zhang, A., Timmerman, C., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav6473 · Cited by 41 · see citing works

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer

Hellmann, M. D., Gettinger, S. N., Chow, L. Q. M., Gordon, M. S., Awad, M. M., Cha, E., Gong, X., Zhou, G., Walker, C., Leopold, L. H., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32951 · Cited by 39 · see citing works

Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).

Felip, E., de Braud, F., Maur, M., Loong, H. H.-F., Shaw, A. T., Vansteenkiste, J., John, T., Liu, G., Lolkema, M. P., Scott, J. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2502 · Cited by 37 · see citing works

The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer

Perdrizet, K., & Leighl, N. B. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0617-6 · Cited by 35 · see citing works

Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with <i>ALK</i> Translocation

Patel, S. P., Pakkala, S., Pennell, N. A., Reckamp, K. L., Lanzalone, S., Polli, A., Tarazi, J., & Robert-Vizcarrondo, F. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0034 · Cited by 34 · see citing works

Mutant KRAS at the heart of tumor immune evasion

van Maldegem, F., & Downward, J. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.013 · Cited by 32 · see citing works

Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice

Jia, Y., Zhao, S., Jiang, T., Li, X., Zhao, C., Liu, Y., Han, R., Qiao, M., Liu, S., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.016 · Cited by 27 · see citing works

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

Thress, K. S., Jacobs, V. N., Angell, H. K., Yang, J. C., Sequist, L. V. D., Blackhall, F. H., Su, W., Schüler, M., Wolf, J., Gold, K. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.011 · Cited by 25 · see citing works

A phase Ib study of SHR-1210 plus apatinib for heavily previously treated advanced non-squamous non-small cell lung cancer (NSCLC) patients.

Zhou, C., Gao, G., Wu, F., Chen, X., Li, W., Xiong, A., Su, C., Cai, W., Ren, S., Jiang, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e21017 · Cited by 15 · see citing works

P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC

Rudin, C., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D., Schmid, P., Heist, R., Villaflor, V., Sarkar, I., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.1841 · Cited by 14 · see citing works

Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

Herbst, R. S., Martín-Liberal, J., Calvo, E., Isambert, N., Bendell, J. C., Cassier, P. A., Jin, J., Mi, G., Rege, J. M., & Paz-Ares, L. G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx091.010 · Cited by 13 · see citing works

IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Mok, T. S. K., West, H., Nishio, M., Papadimitrakopoulou, V. A., Orlandi, F., Stroyakovskiy, D., Thomas, C. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9012 · Cited by 9 · see citing works

Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).

Cho, B. C., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C., Flor, M. J., Nicola, M. A. D., Alvarez, R. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9558 · Cited by 9 · see citing works

AB053. P-21. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): efficacy by BTC subtype

Yoo, C., Oh, D., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., Chen, L., Osada, M., Helwig, C., Dussault, I., et al. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.ab053 · Cited by 7 · see citing works

M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype

Yoo, C., Oh, D., Choi, H. J., Kudo, M., Ueno, M., Kondo, S., Chen, L.-T., Osada, M., Helwig, C., Dussault, I., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy432.005 · Cited by 4 · see citing works

Abstract CT189: Improved progression-free and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial

Yap, T. A., Gainor, J. F., Callahan, M. K., Falchook, G. S., Pachynski, R. K., LoRusso, P. M., Kummar, S., Gibney, G. T., Burris, H. A., Tykodi, S. S., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct189 · Cited by 2 · see citing works

Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC

Ouwens, M., Darilay, A. T., Zhang, Y., Mukhopadhyay, P., Mann, H., Ryan, J., & Dennis, P. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz067 · Cited by 1 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Chu, X., Tian, W., Wang, Z., Zhang, J., & Zhou, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01800-3 · Cited by 222 · see citing works

Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance

Ashrafi, A., Akter, Z., Modareszadeh, P., Modareszadeh, P., Berisha, E., Alemi, P. S., Castro, M. D. C. C., Deese, A. R., & Li, Z. (2022) · Cancers · doi:10.3390/cancers14194562 · Cited by 193 · see citing works

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

Li, Y., Mao, T., Wang, J., Zheng, H., Hu, Z., Cao, P., Yang, S., Zhu, L., Guo, S., Zhao, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01082-8 · Cited by 116 · see citing works

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

Jiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 92 · see citing works

Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives

Zhang, H., Jiang, H., Zhu, L., Li, J., & Ma, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.009 · Cited by 84 · see citing works

Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10

Huang, M., Chen, Y., Lyu, W.-Y., He, X., Ye, Z.-H., Huang, C.-Y., He, X., Chen, X., Chen, X., Zhang, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106988 · Cited by 70 · see citing works

Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function

Yü, P., Shan, J., Liu, Y., Liu, F., Wang, L., Liu, Z., Li, J., Yue, D., Wang, L., Chen, X., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03308-z · Cited by 59 · see citing works

CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells

Zhang, Y., Hu, J., Ji, K., Jiang, S., Dong, Y., Sun, L., Wang, J., Hu, G., Chen, D., Chen, K., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101151 · Cited by 61 · see citing works

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Chen, M., Bie, L., & Ying, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115514 · Cited by 59 · see citing works

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer

Yang, Z., Wu, G., Zhang, X., Gao, J., Meng, C., Liu, Y., Wei, Q., Sun, L., Wei, P., Bai, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001444 · Cited by 56 · see citing works

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment

Zheng, J., Huang, J., Zhang, L., Wang, M., Xu, L., Dou, X., Leng, X., Fang, M., Sun, Y., & Wang, Z. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00350-5 · Cited by 54 · see citing works

Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells

Chen, Y., He, X., Lu, Q., Shi, W., Yuan, L., Huang, M., Xu, Y., Chen, X., Gu, L., Zhang, L., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114940 · Cited by 48 · see citing works

Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination

Sun, Z., Mai, H., Xue, C., Fan, Z., Li, J., Chen, H., Huo, N., Kang, X., Tang, C., Fang, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007415 · Cited by 48 · see citing works

Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway

Lu, Y., Zhong, W., Liu, Y., chen, W., zhang, J., Zeng, Z., Huang, H., qiao, Y., Wan, X., Meng, X., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108504 · Cited by 48 · see citing works

Radiological artificial intelligence - predicting personalized immunotherapy outcomes in lung cancer

Roisman, L. C., Kian, W., Anoze, A., Fuchs, V., Spector, M., Steiner, R., Kassel, L., Rechnitzer, G., Fried, I., Peled, N., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00473-x · Cited by 43 · see citing works

Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma

Jiang, A., Wang, J., Liu, N., Zheng, X., Li, Y., Ma, Y., Zheng, H., Chen, X., Fan, C., Zhang, R., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.833797 · Cited by 42 · see citing works

Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives

Ye, Z.-H., Yu, W., Huang, M., Chen, J., & Lu, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.016 · Cited by 40 · see citing works

A Spatial Quantitative Systems Pharmacology Platform spQSP-IO for Simulations of Tumor–Immune Interactions and Effects of Checkpoint Inhibitor Immunotherapy

Gong, C., Ruiz-Martínez, Á., Kimko, H. H. C., & Popel, A. S. (2021) · Cancers · doi:10.3390/cancers13153751 · Cited by 39 · see citing works

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC

Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.769124 · Cited by 39 · see citing works

Blockade of T‐cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV‐related HCC in mice

Wu, Y., Hao, X., Wei, H., Sun, R., Chen, Y., & Tian, Z. (2022) · Hepatology · doi:10.1002/hep.32715 · Cited by 35 · see citing works

Modern therapies of nonsmall cell lung cancer

Jachowski, A., Marcinkowski, M., Szydłowski, J., Grabarczyk, O., Nogaj, Z., Marcin, L. P., Pławski, A., Jagodziński, P. P., & Słowikowski, B. K. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00786-4 · Cited by 35 · see citing works

Single-cell RNA sequencing reveals enhanced antitumor immunity after combined application of PD-1 inhibitor and Shenmai injection in non-small cell lung cancer

Yu, D., Yang, P., Lu, X., Huang, S., Liu, L., & Fan, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01184-3 · Cited by 30 · see citing works

Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors

Nie, D., Guo, T., Yue, M., Li, W., Zong, X., Zhu, Y., Huang, J., & Lin, M. (2022) · Biomolecules · doi:10.3390/biom12091239 · Cited by 32 · see citing works

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy

Godiyal, Y., Maheshwari, D., Taniguchi, H., Zinzuwadia, S. S., Díaz, Y. M., Tewari, D., & Bishayee, A. (2024) · Military Medical Research · doi:10.1186/s40779-024-00586-9 · Cited by 31 · see citing works

Immunology and immunotherapy in gastric cancer

Xu, X., Chen, J., Li, W., Feng, C., Liu, Q., Gao, W., & He, M. S. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01104-2 · Cited by 28 · see citing works

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Lin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27 · see citing works

Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis

Choi, Y., & Kim, N. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230085 · Cited by 30 · see citing works

A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov

Yang, J., Kang, H., Lyu, L., Xiong, W., & Yuanjia, H. (2023) · Discover Oncology · doi:10.1007/s12672-023-00758-4 · Cited by 25 · see citing works

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Cheng, Y., Song, Z., Chen, J., Tang, Z., & Wang, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25895 · Cited by 25 · see citing works

PD ‐1: A critical player and target for immune normalization

Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 26 · see citing works

Sintilimab, stereotactic body radiotherapy and granulocyte–macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial

Ni, J., Zhou, Y., Wu, L., Ai, X., Dong, X., Chu, Q., Han, C., Wang, X., & Zhu, Z. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01905-3 · Cited by 24 · see citing works

GAPDH Is a Novel Ferroptosis-Related Marker and Correlates with Immune Microenvironment in Lung Adenocarcinoma

Ouyang, X., Zhu, R., Lin, L., Wang, X., Zhuang, Q., & Hu, D. (2023) · Metabolites · doi:10.3390/metabo13020142 · Cited by 24 · see citing works

P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K/Akt pathways

Bai, X., Li, Q., Peng, X., Li, X., Qiao, C., Tang, Y., & Zhao, R. (2023) · Purinergic Signalling · doi:10.1007/s11302-023-09928-z · Cited by 24 · see citing works

Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

Song, L., Wang, X., Wang, C., Wu, Y. M., Liu, M., Liu, R., Zhang, S., Hong, X., Liu, H., Tai, X., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01796-w · Cited by 23 · see citing works

Contribution of skeletal muscle to cancer immunotherapy: A focus on muscle function, inflammation, and microbiota

Deng, Y., Zhao, L., Huang, X., Zeng, Y., Xiong, Z., & Zuo, M. (2022) · Nutrition · doi:10.1016/j.nut.2022.111829 · Cited by 23 · see citing works

New prospects of cancer therapy based on pyroptosis and pyroptosis inducers

Chen, Q., Sun, Y., Wang, S., & Xu, J. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01906-5 · Cited by 23 · see citing works

HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top

Aliaga, P. T., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Signore, E. D., Passaro, A., & de Marinis, F. (2025) · Molecules · doi:10.3390/molecules30122645 · Cited by 22 · see citing works

SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer

Zhao, J., Yu, X., Huang, D., Ma, Z., Gao, B., Cui, J., Chu, Q., Zhou, Q. H., Sun, M., Day, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006055 · Cited by 22 · see citing works

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment

Ailia, M. J., Heo, J., & Yoo, S. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076495 · Cited by 22 · see citing works

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy

Jia, L., Chen, N., Chen, X., Niu, C. S., Liu, Z., Ma, K., Wang, N., Yang, L., Zhao, Y., Song, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074906 · Cited by 21 · see citing works

Sintilimab plus Bronchial Arterial Infusion Chemotherapy/Drug-Eluting Embolic Chemoembolization for Advanced Non–Small Cell Lung Cancer: A Preliminary Study of 10 Patients

Li, Y., Guo, R., Bie, Z., Li, B., & Li, X. (2021) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2021.08.019 · Cited by 20 · see citing works

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study

Chu, X., Qiang, H., Xie, M., Li, X., Zhao, J., Wu, Y., Zhou, J., Ye, J., Zhao, C., Han, C., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03100-5 · Cited by 19 · see citing works

High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation

LIU, L. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028227 · Cited by 19 · see citing works

Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization

Cheng, Y., Han, X., Lai, X., & Wei, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156093 · Cited by 18 · see citing works

Preliminary anticancer evaluation of new Pd(II) complexes bearing NNO donor ligands

Hussain, S., Hussain, S., Zafar, M. N., Hussain, I., Khan, F., Mughal, E. U., & Tahir, M. N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101915 · Cited by 18 · see citing works

Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer

Cui, X., Li, C., Ding, J., Yao, Z., Zhao, T., Guo, J., Wang, Y., & Li, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054513 · Cited by 17 · see citing works

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study

Dou, X.-J., Ma, R.-Y., Ren, D.-W., Liu, Q., & Yan, P. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s444884 · Cited by 17 · see citing works

Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer

Yao, Y., Tao, G., Xie, D., Xu, Y., & Liang, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104861 · Cited by 16 · see citing works

Comprehensive Analysis of Programmed Cell Death Signature in the Prognosis, Tumor Microenvironment and Drug Sensitivity in Lung Adenocarcinoma

Pan, S., Meng, H., Fan, T. T., Hao, B., Song, C., Li, D., Li, N., & Geng, Q. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.900159 · Cited by 16 · see citing works

Identification of a ceRNA Network in Lung Adenocarcinoma Based on Integration Analysis of Tumor-Associated Macrophage Signature Genes

Zhang, L., Zhang, K., Liu, S., Zhang, R., Yang, Y., Wang, Q., Zhao, S., Li, Y., Zhang, Y., & Wang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629941 · Cited by 15 · see citing works

Claudin-7 deficiency induces metabolic reprogramming of neutrophils in the colorectal cancer microenvironment

Liang, X., Yuan, D., Zhao, S., Zhou, J., Wang, K., Liu, X., Liu, Y., Li, H., Hao, M., Huang, W., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08064-3 · Cited by 14 · see citing works

Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma

Liu, Z., Cheng, X., Pang, B., Wang, S., Liu, B., Chen, C., Qian, R., Liang, W., Zhu, Y., Li, P., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108399 · Cited by 14 · see citing works

Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients

Ma, N., Qiao, H., Tao, H., Gan, X., Shan, Z., Chen, X., & Zhou, X. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101962 · Cited by 14 · see citing works

METTL14 regulates CD8+T-cell activation and immune responses to anti‐PD‐1 therapy in lung cancer

Sun, C., Wang, J., Li, H., Liu, L., Lin, Y., Zhang, L., Zu, X., Zhu, Y., Shu, Y., Shen, D., et al. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03402-9 · Cited by 13 · see citing works

Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts

Wang, H., Li, Z., Ou, S., Song, Y., Luo, K., Guan, Z., Zhao, L., Huang, R., & Yu, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.884839 · Cited by 13 · see citing works

Application of Nanoparticles in Tumour Targeted Drug Delivery and Vaccine

Tu, Y., Yao, Z., Yang, W., Tao, S., Li, B., Wang, Y., Su, Z., & Li, S. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.948705 · Cited by 12 · see citing works

Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in non–small cell lung cancer

Villaruz, L. C., Blumenschein, G. R., Otterson, G. A., & Leal, T. A. B. (2023) · Cancer · doi:10.1002/cncr.34683 · Cited by 12 · see citing works

First‐line immune‐based combination therapies for advanced non‐small cell lung cancer: A Bayesian network meta‐analysis

Mao, Z., Jiang, P., Zhang, Y., Li, Y., Jia, X., Wang, Q., Jiao, M., Jiang, L., Shen, Y. L., & Guo, H. (2021) · Cancer Medicine · doi:10.1002/cam4.4405 · Cited by 11 · see citing works

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy

Zeng, W., Pan, J., Fang, Z., Jia, J., Zhang, R., He, M., Zhong, H., He, J., Yang, X., Shi, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925217 · Cited by 11 · see citing works

Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment

Xiang, Y., Tang, L. C., Pang, H., Han, X., He, Y., Feng, Y., Ju, L., Zhang, L., & Wang, D. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s464830 · Cited by 11 · see citing works

GPRC5A is a potential prognostic biomarker and correlates with immune cell infiltration in non-small cell lung cancer

Lin, Y., Wang, Y., Xue, Q., Zheng, Q., Chen, L., Yan, J., Huang, Z., & Li, Y. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-739 · Cited by 10 · see citing works

Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions

Ershov, P. V., Mezentsev, Y. V., & Ivanov, A. S. (2022) · Biomolecules · doi:10.3390/biom12010106 · Cited by 10 · see citing works

Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function

Zou, W., Luo, X., Gao, M., Chang, Y., Wan, X., Yu, S., Wu, Y., Wang, A., Fenical, W., Wei, Z., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16054 · Cited by 10 · see citing works

Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer

Moreira, R. S., da Silva, M. M., Vasconcelos, C. F. D. M., da Silva, T. D., Cordeiro, G. G., Mattos, L. A. R., Pitta, M. G. D. R., Rêgo, M. J. B. D. M., & Pereira, M. C. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05437-z · Cited by 9 · see citing works

An On‐Treatment Decreased Trend of Serum IL‐6 and IL‐8 as Predictive Markers Quickly Reflects Short‐Term Efficacy of PD‐1 Blockade Immunochemotherapy in Patients with Advanced Gastric Cancer

Liu, J., Mao, Y., Mao, C., Wang, D., Dong, L., & Zhu, W. (2024) · Journal of Immunology Research · doi:10.1155/2024/3604935 · Cited by 9 · see citing works

Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy

Zhen, S., Wang, W., Qin, G., Lu, T., Li, Y., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1316778 · Cited by 8 · see citing works

β-elemene inhibits tumor-promoting in small cell lung cancer by affecting M2 macrophages and TGF-β

Huang, W., Fu, B., & Xu, H. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03533-z · Cited by 8 · see citing works

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment

Li, F., Liao, B.-C., Wang, T., Qi, T., & Wang, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918709 · Cited by 8 · see citing works

Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer

Pourali, G., Zafari, N., Velayati, M., Mehrabadi, S., Maftooh, M., Hassanian, S. M., Mobarhan, M. G., Ferns, G. A., Avan, A., & Khazaei, M. (2023) · Current Drug Targets · doi:10.2174/0113894501264450231129042256 · Cited by 8 · see citing works

Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy

Zhang, Y., Chen, X., Hu, B., Zou, B., & Xu, Y. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2374230 · Cited by 8 · see citing works

LSD1 inhibition sensitizes anti-PD1 blockade immunotherapy by inhibiting the long-range attack of tumor-derived extracellular vesicles

Zhao, Y., Zhang, D., Meng, L., Shan, S., Zhang, C., Deng, Z., Han, C., & Kong, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.030 · Cited by 7 · see citing works

Plasma Immune Proteins and Circulating Tumor DNA Predict the Clinical Outcome for Non-Small-Cell Lung Cancer Treated with an Immune Checkpoint Inhibitor

Stensgaard, S., Thomsen, A., Helstrup, S., Meldgaard, P., & Sørensen, B. S. (2023) · Cancers · doi:10.3390/cancers15235628 · Cited by 6 · see citing works

Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma

Luo, Y., Zhang, S., Xie, H., Su, Q., He, S., & Lei, Z. (2023) · Cellular and Molecular Biology · doi:10.14715/cmb/2023.69.14.9 · Cited by 6 · see citing works

Solid Phase Synthesis, DFT Calculations, Molecular Docking, and Biological Studies of Symmetrical N2,N4,N6-Trisubstituted-1,3,5-triazines

Akbar, W., Ehsan, S., Siddique, S. A., Sarfraz, M., Shaheen, F., Shafqat, A., Shahnaz, Siddique, M. B. A., Saeed, A., Al‐Salahi, R. A., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c01980 · Cited by 6 · see citing works

Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma

Wang, P., Wang, Z., Lin, Y., Castellano, L., Stebbing, J., Zhu, L., & Peng, L. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00757-4 · Cited by 6 · see citing works

Anthraquinones from the roots of Morinda scabrida Craib exhibit antiproliferative activity against A549 lung cancer cells and antitubulin polymerization

Sae-Lim, S., Ngiwsara, L., Lirdprapamongkol, K., Puttamuk, T., Maneeanakekul, S., Thangsan, P., Sangsuwan, W., Svasti, J., & Chuawong, P. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105781 · Cited by 6 · see citing works

Construction and analysis of a lysosome-dependent cell death score-based prediction model for non-small cell lung cancer

Fu, J., Chen, Y. S., Li, J., Tan, M., Lin, R., Wang, J., Wu, G., Rao, Y., Wu, F., Gao, Y., et al. (2024) · Discover Oncology · doi:10.1007/s12672-024-01233-4 · Cited by 5 · see citing works

Identification of STAT3 phosphorylation inhibitors using generative deep learning, virtual screening, molecular dynamics simulations, and biological evaluation for non-small cell lung cancer therapy

Cai, W., Jiang, B., Yin, Y., Ma, L., Li, T., & Chen, J. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11067-5 · Cited by 5 · see citing works

Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial)

Liu, X., Sui, X.-Y., Xu, Y., Yang, F., Wu, S., Zhu, X.-Z., Zuo, K., Cao, S.-W., Jin, X., Chen, L., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02505-5 · Cited by 4 · see citing works

Integrated Bulk and Single-cell RNA Sequencing Data Constructs and Validates a Prognostic Model for Non-small Cell Lung Cancer

Zhu, J., Yang, J., Chen, X., Wang, Y., Wang, X., Zhao, M., Li, G., Wang, Y., Zhu, Y., Yan, F., et al. (2024) · Journal of Cancer · doi:10.7150/jca.90768 · Cited by 4 · see citing works

The anticancer mechanisms of Toxoplasma gondii rhoptry protein 16 on lung adenocarcinoma cells

Li, G., Li, Q., Tong, Y., Zeng, J., Dang, T., Yang, N., Zhou, Y., Ma, L., Ge, Q. Y., & Zhao, Z. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2392902 · Cited by 4 · see citing works

Establishment and Validation of an Interferon-Stimulated Genes (ISGs) Prognostic Signature in Pan-cancer Patients: A Multicenter, Real-world Study

Zhou, Z., Zheng, Y., Mo, S., Li, S., Zheng, X., Wei, R., Fan, T. T., Chen, T., Xiao, C., Li, C., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71385 · Cited by 4 · see citing works

PMSG-Net: A priori-guided multilevel graph transformer fusion network for immunotherapy efficacy prediction

Yang, W., Wu, W., Wang, L., Zhang, S., Zhao, J.-J., & Qiang, Y. (2023) · Comput. Biol. Medicine · doi:10.1016/j.compbiomed.2023.107371 · Cited by 4 · see citing works

Dihydrotanshinone I inhibits PHGDH to suppress serine synthesis and remodel TME in NSCLC

Qian, C., Han, H., Wan, L., Huang, Y., Luo, Y., Wang, Z., Peng, C., Gao, M., Fan, W., Lu, Y., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158366 · Cited by 3 · see citing works

Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells

Yu, W., Ye, Z.-H., Shi, J.-J., Deng, W.-Q., Chen, J., & Lu, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116898 · Cited by 3 · see citing works

Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells

Wang, R.-H., Chang, C., Chen, C., Liu, K., & Chao, J. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230223111217 · Cited by 3 · see citing works

Discovery of a novel ROS-based signature for predicting prognosis and immunosuppressive tumor microenvironment in lung adenocarcinoma

Guo, Y., Chang, G., Wan, R., Zhang, X., Ma, Z., Bai, H., & Wang, J. (2024) · Journal of Cancer · doi:10.7150/jca.93975 · Cited by 4 · see citing works

Research progress of anti-tumor active ingredients in Dandelion

Xie, J., Huang, Y., & Wang, Q. (2020) · Journal of Oncology Research · doi:10.30564/jor.v2i2.2472 · Cited by 3 · see citing works

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors

Zhai, M., Ji, S., Hu, H., Wu, Y., Shi, Y., Zhu, R., Jiang, Y., & Yang, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1533541 · Cited by 2 · see citing works

Targeting the Toll-like Receptor Signaling Pathway in Lung Cancer: Therapeutic Opportunities and Challenges

Usama, M., Raza, B., Wu, M., & Ji, S. (1970) · Current Drug Targets · doi:10.2174/0113894501414090250903070446 · Cited by 2 · see citing works

Accurate diagnosis of triple-negative breast cancer enables temperature-compensation all optical microfibre gratings system

Liu, X., Xu, Q., Wang, Y., Wang, C., Liang, W., Huang, L., Lü, L., Lv, J., Gao, J., Yu, B., et al. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.118706 · Cited by 2 · see citing works

The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials

Duan, X., Du, H., Qi, R., Yuan, M., & Shi, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11915 · Cited by 2 · see citing works

Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study

Firoozi, M., Sadeghi‐Mohammadi, S., Asadi, M., Shekari, N., Nejad, F. S., Alizade‐Harakiyan, M., Soleimani, Z., & Zarredar, H. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3919 · Cited by 2 · see citing works

Antibiotic adoption effects on nutrition and quality of life in lung cancer patients undergoing radiotherapy and chemotherapy: A meta-analysis

Zhao, Z., & Yua, Y. (2024) · Technology and Health Care · doi:10.3233/thc-240660 · Cited by 2 · see citing works

Unraveling tumoral heterogeneity and angiogenesis-associated mechanisms of PD-1 and LAG-3 dual inhibition in lung cancers by single-cell RNA sequencing

Zhao, L., Tang, C., Jin, X. S., Wang, H., Xu, K., Liu, X., Liu, Y., Zhao, W., Zhang, W., Ye, L., et al. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.004 · Cited by 2 · see citing works

Construction of a prognostic risk model based on pyroptosis-related genes and comprehensive analysis of key genes and tumor immune microenvironment for colon cancer

Liu, M., Zhang, J., Zhao, Y., & Zhang, X. (2024) · Medicine · doi:10.1097/md.0000000000039300 · Cited by 1 · see citing works

Immunotherapy in advanced colorectal cancer: Current landscape, mechanisms, challenges, and future directions

Huang, J., & Tian, G. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251414845 · Cited by 1 · see citing works

[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer].

Zhang, N., Wang, X., Shen, J., Sun, S., Shen, Y., & Wang, J. (2022) · PubMed

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies

Sui, H., Ma, N., Wang, Y., Li, H., Liu, X., Su, Y., & Yang, J. (2018) · Journal of Immunology Research · doi:10.1155/2018/6984948 · Cited by 199 · see citing works

Advances in PD-1 inhibitor combination therapy for non-small cell lung cancer

Wang, F. (2025) · MedScien · doi:10.61173/vsnwe981

Combining chemotherapy with PD-1 blockade in NSCLC

Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 145 · see citing works

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?

Qiao, M., Jiang, T., Ren, S., & Zhou, C. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.005 · Cited by 50 · see citing works